CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma - Tian, Meijie; Wei, Jun S.; Cheuk, Adam Tai-Chi; Milewski, David; Zhang, Zhongmei; Kim, Yong Yean; Chou, Hsien-Chao; Liu, Can; Badr, Sherif; Pope, Eleanor G.; Rahmy, Abdelrahman; Wu, Jerry T.; et al. (Nature communications, 2024)
Keywords: 13/31; 38/5; 49/91; 631/250/2152/1566/1618; 631/250/2520; 631/67/1059/2325; 631/67/2332; 82/51; 82/81; Animals; Anticancer properties; Antigens; Antitumor activity; Antitumor agents; B7 Antigens - genetics; B7 Antigens - immunology; B7 Antigens - metabolism; CD28 antigen; CD8 antigen; Cell activation; Cell culture; Cell Line, Tumor; Cell therapy; Child; Childhood; Children; Chimeric antigen receptors; Female; Fibroblast growth factor receptor 4; Growth factors; Heterogeneity; Humanities and Social Sciences; Humans; Immunotherapy, Adoptive - methods; Lymphocytes; Lymphocytes T; Mice; Mice, Inbred NOD; Mice, SCID; Microenvironments; multidisciplinary; MyoD Protein - genetics; MyoD Protein - metabolism; Receptor, Fibroblast Growth Factor, Type 4 - genetics; Receptor, Fibroblast Growth Factor, Type 4 - metabolism; Receptors; Receptors, Chimeric Antigen - immunology; Receptors, Chimeric Antigen - metabolism; Rhabdomyosarcoma; Rhabdomyosarcoma - genetics; Rhabdomyosarcoma - immunology; Rhabdomyosarcoma - therapy; Science; Science (multidisciplinary); Solid tumors; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Target recognition; Transmembrane domains; Tumors; Tyrosine; Xenograft Model Antitumor Assays; Xenotransplantation